Hot Biotech Stocks To Buy For 2019

tags:ARQL,ALNY,BIIB,AMGN,

Sometimes you just have to pay respects to a great company and its leadership. A track record of excellent returns on invested capital, a great balance sheet, and stable earnings created through consistent customer service. Laudable indeed are the results of these high performers who bring service and value to society!

In this article we're going to cover the praiseworthy WABCO Holdings Inc (NYSE:WBC). We'll take a look at the fundamentals of their business, the returns they've earned, and, the recent trading action going on in the marketplace.

Research And Development: It Isn't Just A Biotech Thing

Click to enlarge

Hot Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Lisa Levin] Gainers Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy. Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings. Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS. Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter. Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625. ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday. Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results. Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94. ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07. Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50. Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000. Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64. Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90. Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock. Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55. Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

  Check out these big penny stock gainers and losers

• [By Money Morning Staff Reports]

  But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we'll show you a small-cap stock with great profit potential in its future…

  Penny Stock Current Share Price Law Month's Gain  Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85% Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40% Vivis Inc. (Nasdaq: VVUS) $0.77 150.41% Adomani Inc. (Nasdaq: ADOM) $1.49 137.68% NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88% Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06% Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12% ArQule Inc. (Nasdaq: ARQL) $4.88 90.74% LiqTech International Inc. (NYSE: LIQT) $0.66 85.60% Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

  While last month's gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

• [By Ethan Ryder]

  ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

• [By Logan Wallace]

  BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

  A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

• [By Logan Wallace]

  ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

  Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

Hot Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Todd Campbell]

  Spark Therapeutics (NASDAQ:ONCE) reported its hemophilia A drug significantly reduced bleeding events and the need for prophylactic factor VIII infusions, but investors sold shares on worry that the gene therapy's safety could be a problem. Investors similarly headed for the exits with Rite Aid (NYSE:RAD) and Alnylam Pharmaceuticals (NASDAQ:ALNY) after the former scuttled an attempt to sell itself and the latter secured a first-in-class FDA approval. Are these falling stocks worth buying?

• [By Cory Renauer]

  After 16 years as a public company, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) finally got the go-ahead to launch its first product earlier this month. Onpattro is the first in a new class of drugs that alter gene expression, but Pfizer, Inc. (NYSE:PFE) just reported some impressive results with a possible competitor that works a lot differently.

• [By Ethan Ryder]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Tuesday.

• [By Joseph Griffin]

  BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

• [By Sean Williams, Chuck Saletta, and Brian Feroldi]

  So, which biotech stocks should you consider buying in June? That's a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

• [By Max Byerly]

  Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Sean Williams, Chuck Saletta, and Brian Feroldi]

  As noted, the ability to take numerous swings for the fence makes Ionis special. It's often a marvel when a mid-cap drugmaker has a half-dozen experimental drugs, let alone one working with 25. Spinal muscular atrophy drug Spinraza, which was licensed to Biogen (NASDAQ:BIIB), is one such drug that's put Ionis and its antisense technology on the map. Last year, Spinraza netted "just" $882 million in total sales, but delivered $364 million globally in the first quarter of 2018. That extrapolates out to more than $1.4 billion, which means added royalty revenue for Ionis.

• [By Chris Lange]

  Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 2.85 million shares from the previous 3.59 million. The stock recently traded at $316.87, within a 52-week range of $249.17 to $388.67.

• [By George Budwell]

  Shares of large-cap biotech Biogen (NASDAQ:BIIB) gained a healthy 15.2% in July, according to data from S&P Global Market Intelligence. What triggered this breakout? 

• [By Trey Thoelcke]

  Biogen Inc. (NASDAQ: BIIB) also saw a death cross earlier this month, and the gap between the moving averages is now more than 9% of the share price. The stock was just downgraded by one analyst and another recently anticipated no growth in the share price. The stock is up more than 6% since the beginning of the year. The consensus recommendation remains to buy Biogen shares.

• [By George Budwell]

  Biotech heavyweight Biogen (NASDAQ:BIIB) has now lost over 13% of its value so far this year. To be fair, this year hasn't been kind to biotechs in general, thanks to President Trump's aggressive trade policies with China. But Biogen's value has been declining at a far faster rate than the industry as a whole due to stiffer competition in the all-important multiple sclerosis (MS) space.

• [By Cory Renauer]

  Ionis still has a 75% stake in Akcea, but Waylivra's CRL is more of a speed bump than a roadblock for the RNA antisense pioneer. Investors probably don't need to worry about potential partners avoiding Ionis because of Waylivra's mishap. Spinraza, an Ionis drug that Biogen (NASDAQ:BIIB) launched at the end of 2016, hit an annualized $1.7 billion run rate in the second quarter.

Hot Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Keith Speights]

  Amgen (NASDAQ:AMGN) ranks No. 1 among all biotech stocks when it comes to market cap. It's one of the most profitable biotechs and claims one of the largest cash stockpiles in the industry.

• [By Todd Campbell]

  Neulasta has been one of Amgen's (NASDAQ:AMGN) crown jewels for years, but following FDA approval of Mylan's (NASDAQ:MYL) Neulasta biosimilar this week, Amgen could see Neulasta's revenue slow to a trickle. Is Mylan about to deliver a big blow to Amgen's market share? Read on to find out what's at stake for these companies and their investors.

• [By Stephan Byrd]

  Cpwm LLC increased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 59.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,702 shares of the medical research company’s stock after purchasing an additional 3,253 shares during the period. Cpwm LLC’s holdings in Amgen were worth $1,606,000 at the end of the most recent quarter.

Here’s Why Chipotle Stock Will Plummet on Any Negative Headline

Make no mistake about it. Chipotle (NYSE:CMG) is finally back. The E. coli outbreak which hit the chain hard in 2015 is now in the rear-view mirror. The company is using new marketing, menu innovations and an expanded digital presence to drive a long overdue recovery in traffic, sales and margins. In response, CMG stock has rallied from $250 in February 2018, to $660 a little over a year later.

Source: Shutterstock

Some bulls think this monster rally will continue. Piper Jaffray recently lifted its price target on CMG stock to $725, citing international expansion potential as a reason to buy Chipotle stock.

But fundamentals say that this big Chipotle stock rally is on its last legs. To be sure, the fundamentals at Chipotle are improving. Unique marketing campaigns, healthy food menu innovations, and digital business expansions are driving robust and sustainable comparable sales and traffic growth. That’s pushing margins higher. Plus, the company still has a ton of runway left on the unit expansion front (only 2,500 stores).

But all of those positives are already priced into CMG stock. This is a $650 stock with a fiscal 2019 earnings estimate of $12.30 per share. That means Chipotle stock is trading at over 50x forward earnings. The average forward multiple in the restaurant sector is under 25. Thus, CMG stock is trading at more than double the valuation of its peers.

Even for a company with as big of growth potential as Chipotle, that relative valuation gap is just too large. It will eventually narrow, and in a big way, meaning that Chipotle stock is due for a sizable correction in the near future.

The Fundamentals Are Improving

The Chipotle turnaround is very real and very impressive.

Long story short, Chipotle brought in new CEO Brian Niccol about a year ago, and he’s done nothing short of a spectacular job turning around what was a sinking ship. Before Niccol, Chipotle was a company struggling with its brand image, which had no real growth drivers in the aftermath of a crippling late 2015 E. coli outbreak.

Since Niccol took over, all that has changed. Chipotle has re-branded itself as a healthy QSR chain with real ingredients through its new ‘For Real’ marketing campaign. To coincide with that marketing campaign, Chipotle has also expanded its menu to include things like lifestyle bowls, which cater to the ingredient-sensitive consumer. Meanwhile, Chipotle has also significantly expanded its presence on digital food-ordering apps.

These three initiatives have worked wonders for Chipotle. Traffic growth has turned healthily positive for the first time since late 2015. Comparable sales growth is running around 10%-plus. Digital sales growth was above 65% last quarter. Restaurant level operating margins are moving consistently higher.

In other words, the Chipotle turnaround is here. It won’t end any time soon. As such, the fundamentals underlying CMG stock project to remain favorable for a lot longer.

The Valuation Makes No Sense

At current levels, favorable long-term growth fundamentals won’t cut it for CMG stock. It’s already priced for favorable long-term growth, and then some.

Compare Brokers

This is a restaurant stock trading at over 50x forward earnings. The whole market trades at 16x forward earnings. Restaurant stocks trade at 23x forward earnings. High growth application software stocks trade at 35 forward earnings. Indeed, on a forward earnings basis, CMG stock is more expensive than Facebook (NASDAQ:FB), Alphabet (NASDAQ:GOOG), Twitter (NYSE:TWTR), Adobe (NASDAQ:ADBE), Alibaba (NYSE:BABA), and Intuitive Surgical (NASDAQ:ISRG), all 20%-plus revenue-growth tech companies with sky high margins and big moats. It’s also nearly as expensive as Amazon (NASDAQ:AMZN) and Salesforce (NYSE:CRM), two huge revenue-growth companies with tremendous margin expansion potential.

That doesn’t make much sense to me. Again, CMG is a restaurant stock. With a sub-10% revenue growth rate. In a competitive fast casual restaurant industry. And margins that, while heading higher, don’t have that much more room to expand.

Here’s my math on Chipotle stock. Mid-single-digit comparable sales growth will likely slow going forward as the lap gets tougher. But comps will remain in the low single-digit range thanks to menu innovations and digital business expansion. Sustained mid-single-digit unit growth should drive high-single-digit revenue growth. Restaurant level margins should continue to rise, but flatten out short of their mid-2010’s highs due to higher labor costs. G&A and D&A expense rates should fall with scale.

Putting all together, I optimistically see Chipotle as a 20% earnings grower over the next several years, with potential to hit $35 in EPS by fiscal 2025. Based on a slightly above restaurant-average 25x forward multiple, that equates to a fiscal 2024 price target for CMG stock of $875. Discounted back by 10% per year, that equates to fiscal 2019 price target below $550.

Chipotle stock trades above $650 today. As such, this stock is simply overvalued at the present moment.

Bottom Line on CMG Stock

The Chipotle turnaround is here, and it’s not going anywhere anytime soon. But CMG stock has already had its big run-up in anticipation of this recovery. At current levels, the stock is overvalued. As such, the next time this company fumbles, the stock could drop in a big way, and in the restaurant industry, fumbles happen all the time.

As of this writing, Luke Lango was long  FB, GOOG, TWTR, AD

TittieCoin Market Capitalization Reaches $148,086.00 (TIT)

TittieCoin (CURRENCY:TIT) traded 200.8% higher against the dollar during the one day period ending at 20:00 PM ET on March 14th. During the last seven days, TittieCoin has traded 1.1% lower against the dollar. TittieCoin has a total market capitalization of $148,086.00 and approximately $0.00 worth of TittieCoin was traded on exchanges in the last day. One TittieCoin coin can currently be purchased for $0.0001 or 0.00000003 BTC on popular exchanges including Cryptopia, YoBit and Crex24.

Here is how similar cryptocurrencies have performed during the last day:

Get TittieCoin alerts: Litecoin (LTC) traded 1% higher against the dollar and now trades at $56.60 or 0.01443597 BTC. Dogecoin (DOGE) traded up 0.8% against the dollar and now trades at $0.0020 or 0.00000052 BTC. Verge (XVG) traded 5.1% higher against the dollar and now trades at $0.0069 or 0.00000177 BTC. Bytom (BTM) traded up 6.4% against the dollar and now trades at $0.10 or 0.00002559 BTC. Linkey (LKY) traded up 1.9% against the dollar and now trades at $0.82 or 0.00020924 BTC. Polymath (POLY) traded down 1.6% against the dollar and now trades at $0.0997 or 0.00002542 BTC. Syscoin (SYS) traded down 0.2% against the dollar and now trades at $0.0555 or 0.00001415 BTC. Einsteinium (EMC2) traded 19.9% lower against the dollar and now trades at $0.0800 or 0.00002040 BTC. TTC Protocol (TTC) traded up 28.4% against the dollar and now trades at $0.0571 or 0.00001457 BTC. Matrix AI Network (MAN) traded up 3% against the dollar and now trades at $0.10 or 0.00002573 BTC.

TittieCoin Coin Profile

TittieCoin (CRYPTO:TIT) is a proof-of-work (PoW) coin that uses the Scrypt hashing algorithm. Its launch date was January 29th, 2014. TittieCoin’s total supply is 1,259,816,434 coins. TittieCoin’s official website is tittiecoin.com. TittieCoin’s official Twitter account is @TittieCoin. The Reddit community for TittieCoin is /r/tittiecoin and the currency’s Github account can be viewed here.

TittieCoin Coin Trading

TittieCoin can be purchased on the following cryptocurrency exchanges: Cryptopia, Crex24 and YoBit. It is usually not presently possible to purchase alternative cryptocurrencies such as TittieCoin directly using U.S. dollars. Investors seeking to acquire TittieCoin should first purchase Ethereum or Bitcoin using an exchange that deals in U.S. dollars such as GDAX, Changelly or Gemini. Investors can then use their newly-acquired Ethereum or Bitcoin to purchase TittieCoin using one of the exchanges listed above.

Hot Dividend Stocks To Own Right Now

tags:CSIQ,MOV,VAL,

Eni (E) is an Italian multinational oil and gas company headquartered in Rome. With a $60 billion market cap, Eni is considered one of the global oil and gas super majors. Despite being a super major, Eni has had a difficult time since the start of the oil crash. However, the company's impressive assets compared with the company's respectable dividend yield make the company, as we will see, an impressive investment.

Introduction

Eni was created in Italy in 1953, or 64 years ago by the Italian government. Even today, 30% of the company is held by the Italian government with the People's Bank of China owning another 2%. The remainder of the company is publicly traded. As a result of its large size, Eni is in the top 100 of the Fortune Global 500, or one of the largest 100 companies in the world. This size, along with the major government stake, gives the company significant power.

Click to enlarge

Hot Dividend Stocks To Own Right Now: Canadian Solar Inc.(CSIQ)

Advisors' Opinion:

• [By Paul Ausick]

  Canadian Solar Inc. (NASDAQ: CSIQ) saw a decrease of 5.3% in short interest during the first two weeks of February. Some 6.7% of the total float, or 2.99 million shares, were short, and days to cover fell from four to three. The company’s shares traded down 4.6% over the period, and shares closed Wednesday at $24.19, up about 1.4% for the day, in a 52-week range of $11.37 to $25.02.

• [By Paul Ausick]

  Canadian Solar Inc. (NASDAQ: CSIQ) saw a skyrocketing increase of 133.6% in short interest during the two-week period. Some 2.92 million shares were short and days to cover fell from two to one. The company’s share price dipped by 30% over the two weeks, and shares closed Tuesday at $12.15, down about 2% for the day, in a 52-week range of $11.37 to $19.09.

• [By Paul Ausick]

  Canadian Solar Inc. (NASDAQ: CSIQ) saw a decrease of 13.8% in short interest during the two-week period until May 31. Some 2.8% of the total float, or 1.25 million shares, were short and the number of days to cover fell from three to two. The company’s share price dipped 1.2% over the two-week period. And Monday’s closing price was $12.20, a rise of about 3.1% for the day, within a 52-week range of $12.04 to $19.09.

• [By Garrett Baldwin]
  Yesterday, North Korean officials threatened to pull out of next month's summit with President Donald Trump over demands tied to its nuclear weapons program. The announcement comes when tensions are already high over increasing inflation fears, Japan's economic contraction, and uncertainty around trade between the U.S. and China. Markets are likely to continue to react with uncertainty as the global political climate continues to grow increasingly volatile. WTI crude oil remained near $71.00 despite concerns as markets look to the Energy Information Administration on the state of U.S. inventory levels. Oil prices have been under pressure after the U.S. announced it would pull out of the Iran Nuclear Deal. The American Petroleum Institute projected Tuesday that U.S. stocks increased by 4.9 million barrels to 435 million barrels. The EIA will release its official report later this morning. Three Stocks to Watch Today: M, SBUX, AMZN Macy's Inc. (NYSE: M) will lead another busy day of earnings reports. The retail company's stock surged more than 12% this morning after a huge earnings report that crushed Wall Street expectations. The firm reported EPS of $0.48, topping expectations of $0.37 by 11 cents. The company also beat revenue expectations by roughly $100 million and experienced a huge jump in same-store sales. It doesn't look like the U.S-China trade dispute will impact Starbucks Corporation (Nasdaq: SBUX). The coffee giant announced plans to build 3,000 new stores in China in the coming years. The company aims to double its store-front presence by the end of 2022 and hopes to double its profits and triple its revenue in the nation in the process. Amazon.com (Nasdaq: AMZN) is back in the news as it continues its slash-and-burn campaign against rival grocery store operators. This morning, the company announced it was slashing Whole Foods prices for its Prime members. The new price list includes 10% discounts on hundreds of items. The perks are rolling ou
• [By Lisa Levin]

  Canadian Solar Inc. (NASDAQ: CSIQ) is projected to report quarterly earnings at $0.47 per share on revenue of $1.34 billion.

  Magal Security Systems Ltd. (NASDAQ: MAGS) is expected to report earnings for its first quarter.

• [By Dan Caplinger]

  Wall Street enjoyed a positive session on Monday, with highlights including strong gains for most major benchmarks. Investors found it easier to be optimistic about the prospects for continued economic growth than to be pessimistic about the potential negative outcomes of recent trade disputes between the U.S. and key allies. Even so, some companies had to deal with bad news that hurt them disproportionately and sent their shares lower. Canadian Solar (NASDAQ:CSIQ), Nektar Therapeutics (NASDAQ:NKTR), and Gulfport Energy (NASDAQ:GPOR) were among the worst performers on the day. Here's why they did so poorly.

Hot Dividend Stocks To Own Right Now: Movado Group Inc.(MOV)

Advisors' Opinion:

• [By Steve Symington]

  Shares of Movado Group Inc. (NYSE:MOV) were up 16.5% as of 12:30 p.m. EDT Wednesday after the watchmaker announced strong quarterly results.

  For Movado's fiscal first quarter ended April 30, 2018, net sales grew 28.1% year over year (22.1% in constant currency) to $127.1 million, including roughly $2.2 million related to the adoption of new accounting standards. On the bottom line, that translated to adjusted earnings of $8.7 million, or $0.37 per share, up from $0.01 per share in the same year-ago period.

• [By Ethan Ryder]

  Movado (NYSE:MOV) released its earnings results on Wednesday. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.26, RTT News reports. The firm had revenue of $127.10 million for the quarter, compared to analyst estimates of $109.47 million. Movado had a positive return on equity of 9.78% and a negative net margin of 2.68%. Movado’s revenue was up 28.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.01 earnings per share. Movado updated its FY19 guidance to $2.35-2.40 EPS.

• [By Lisa Levin] Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) rose 7.3 percent to $6.90 in pre-market trading after the company reported the FDA approval of TX-004HR: IMVEXXY (estradiol vaginal inserts) for moderate to severe dyspareunia due to menopause. Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS) rose 6.1 percent to $10.50 in pre-market trading after falling 1.20 percent on Tuesday Movado Group, Inc. (NYSE: MOV) shares rose 5.7 percent to $44.60 in pre-market trading after the company reported better-than-expected Q1 results and raised its guidance. salesforce.com, inc. (NYSE: CRM) rose 5.4 percent to $133.67 in pre-market trading after the company reported better-than-expected earnings for its first quarter and raised its forecast for the full year. Sirius XM Holdings Inc. (NASDAQ: SIRI) rose 5.3 percent to $7.35 in pre-market trading. PagSeguro Digital Ltd. (NYSE: PAGS) rose 5.3 percent to $33.50 in pre-market trading after reporting Q1 results. SpartanNash Co (NASDAQ: SPTN) rose 4.9 percent to $19.80 in pre-market trading after the company reported upbeat earnings for its first quarter on Tuesday. Groupon, Inc. (NASDAQ: GRPN) rose 4.9 percent to $4.95 in pre-market trading. Dalian Wanda will set up a joint venture with Tencent and Groupon's former local unit, Reuters reported. Okta, Inc. (NASDAQ: OKTA) rose 4.4 percent to $56 in pre-market trading after gaining 3.43 percent on Tuesday Elbit Systems Ltd. (NASDAQ: ESLT) rose 4.3 percent to $120.92 in pre-market trading after gaining 2.05 percent on Tuesday. STMicroelectronics N.V. (NYSE: STM) shares rose 3.7 percent to $23.78 in pre-market trading after falling 4.70 percent on Tuesday. EVINE Live Inc (NASDAQ: EVLV) shares rose 2.7 percent to $1.14 in pre-market trading after reporting Q1 results.

  Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Hot Dividend Stocks To Own Right Now: Valspar Corporation (VAL)

Advisors' Opinion:

• [By Max Byerly]

  Valorbit (CURRENCY:VAL) traded 0% higher against the dollar during the 1 day period ending at 11:00 AM Eastern on June 9th. One Valorbit coin can currently be bought for approximately $0.0001 or 0.00000001 BTC on exchanges. Valorbit has a market cap of $537,598.00 and $0.00 worth of Valorbit was traded on exchanges in the last 24 hours. In the last seven days, Valorbit has traded up 5.8% against the dollar.

• [By Shane Hupp]

  Shares of ValiRx Plc (LON:VAL) rose 5.6% during mid-day trading on Thursday . The company traded as high as GBX 1.90 ($0.02) and last traded at GBX 1.90 ($0.02). Approximately 587,748 shares were traded during trading, a decline of 85% from the average daily volume of 3,820,000 shares. The stock had previously closed at GBX 1.80 ($0.02).

• [By Stephan Byrd]

  Valorbit (CURRENCY:VAL) traded up 0% against the U.S. dollar during the 1 day period ending at 0:00 AM E.T. on June 18th. One Valorbit coin can now be bought for approximately $0.0001 or 0.00000001 BTC on popular exchanges. Valorbit has a total market capitalization of $537,598.00 and $0.00 worth of Valorbit was traded on exchanges in the last day. During the last week, Valorbit has traded 5.8% higher against the U.S. dollar.

Buy the Dip in National Beverage Because FIZZ Stock Is Ready to Pop

From the looks of it, National Beverage Corp. (NYSE:FIZZ) is a brand in crisis mode. The parent company of leading sparkling water brand La Croix has seen its growth narrative come off the rails over the past several quarters as competition in the sparkling water category has heated up and broader market growth has cooled for FIZZ stock.

Source: H. Michael Karshis (Modified)

Meanwhile, management appears to be in damage control mode, the PR backlash hasn’t been great, and the outlook for demand and profit growth to return in the near term is bleak.

All together, FIZZ stock has dropped from a 52 week high of $120-plus six months ago, to prices below $60 today.

At this point in time, the bear thesis on FIZZ stock looks pretty compelling. You have a brand that is rapidly losing mind and market share in a slowing market, with falling margins and rising opex rates, too. All together, National Beverage Corp. will likely pivot into an era of sideways profits for the foreseeable future, which should lead to further weakness in FIZZ stock.

That thesis sounds good. But, it misses one big element: valuation.

At current levels, FIZZ stock is dirt cheap. It’s already priced for all those negatives. But, in the event that National Beverage Corp. actually turns sales around and stabilizes margins, this stock could fly higher.

I think that’s what will happen. In the big picture, National Beverage Corp. is losing share in a rapidly growing market that has supported and will continue to support multiple high volume brands. La Croix will be one of those high volume brands. As such, sales will stabilize. So will margins. And profits.

None of that stabilization is priced in today. That’s why now looks like the right time to buy the dip in FIZZ.

The Brand Is Losing Steam

There’s no question about it; La Croix is losing momentum. Revenues rose 18% last year. Then, throughout the course of fiscal 2019, they have fallen from 18% to 13%, to 7%, and finally to down 3% last quarter. As revenue growth has slowed, gross margins have come under pressure, as have opex rates. All together, profit growth has pivoted from hugely positive, to hugely negative.

There’s a few reasons behind this big pivot. First, the sparkling water category is slowing. There’s nothing that National Beverage Corp. can do about this. Sparkling water market growth rates have steadily declined over the past several years, as is only natural for a red hot market with big growth rates.

Second, competition in the sparkling water category has picked up. There’s also nothing that National Beverage Corp. can do about this. More competitors have entered this market, include PepsiCo (NYSE:PEP) with their flavored sparkling water drink Bubly. Those new competitors have stolen share from La Croix.

Compare Brokers

Thus, largely due to no fault of its own, La Croix brand is losing momentum. The financial implications of this are meaningful. Revenue growth will be way slower going forward thanks to falling market share. Gross margins will be pressured for the foreseeable future due to bigger pricing competition. Opex rates will head higher as the company will have to spend more to compete on the awareness front.

Putting all that together, it’s easy to see that National Beverage Corp’s profit growth over the next several years won’t be great. After back-to-back years of 30%-plus profit growth, investors weren’t expecting great. As such, FIZZ has come under significant selling pressure over the past several quarters as weak profit growth has turned into a reality.

The Valuation Is Cheap Enough to Buy

With sales slowing, margins retreating, and profits shrinking, it’s tough to see why you would want to buy FIZZ here. But, the bull thesis is pretty simple. All those negatives are already priced in. Eventually, they will fade out. When they do, the stock will pop in a big way.

The reality is that, while La Croix is losing market share to newer entrants in the sparkling water category, this brand still remains one of, if not the, most important brand in the sparkling water market.

It’s easy to see La Croix’s dominance weakening going forward. But, it’s equally tough to see the brand not being one of the top sparkling water drinks in any time horizon, given that La Croix has become almost synonymous with sparkling water.

As such, La Croix should be able to grow revenues at a slightly slower rate than the entire sparkling water category. The entire sparkling water category projects as a double-digit grower over the next several years. Thus, La Croix should be able to grow revenues at a high single digit rate during that stretch.

Gross margins will come under pressure, but should stabilize as competitive forces stabilize. Opex rates will likewise move higher, but should retreat in the long run thanks to high single digit revenue growth and stabilized competition.

Overall, I think sparkling water market expansion can drive National Beverage’s EPS towards $5 by fiscal 2025, even against a competitive backdrop. Coca-Cola (NYSE:KO) and Pepsi normally trade around 20 forward earnings. Based on that comp average 20 forward multiple, a realistic fiscal 2024 price target for FIZZ stock is $100. Discounted back by 10% per year, that equates to a fiscal 2019 price target of over $60.

FIZZ  trades at under $60 today. Thus, it’s reasonable to say that, even considering all the competitive risks, FIZZ stock is undervalued relative to its long term growth prospects.

Bottom Line on FIZZ Stock

I used to drink a lot of La Croix. Now, I drink some La Croix and some Bubly. Apparently, I’m not the only one who has started drinking Bubly, and FIZZ stock has dropped big as a result.

But, I still drink La Croix, as do a ton of consumers, and the whole sparkling water category is still growing by a ton. Thus, growth in the long run will stabilize and remain healthy. FIZZ stock currently isn’t priced for this. That’s why buying the dip here looks like an opportunity.

As of this writing, Luke Lango was long

Nelson Van Denburg & Campbell Wealth Management Group LLC Raises Holdings in iShares iBoxx $ Inv

Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSEARCA:LQD) by 0.7% in the 4th quarter, HoldingsChannel reports. The firm owned 49,590 shares of the exchange traded fund’s stock after buying an additional 338 shares during the quarter. iShares iBoxx $ Investment Grade Corporate Bond ETF makes up about 1.3% of Nelson Van Denburg & Campbell Wealth Management Group LLC’s portfolio, making the stock its 12th largest position. Nelson Van Denburg & Campbell Wealth Management Group LLC’s holdings in iShares iBoxx $ Investment Grade Corporate Bond ETF were worth $5,594,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Portfolio Solutions LLC purchased a new position in shares of iShares iBoxx $ Investment Grade Corporate Bond ETF in the fourth quarter valued at $28,000. Sterling Investment Advisors Ltd. grew its position in shares of iShares iBoxx $ Investment Grade Corporate Bond ETF by 27.8% in the fourth quarter. Sterling Investment Advisors Ltd. now owns 690 shares of the exchange traded fund’s stock valued at $77,000 after purchasing an additional 150 shares in the last quarter. Essex Savings Bank purchased a new position in shares of iShares iBoxx $ Investment Grade Corporate Bond ETF in the fourth quarter valued at $79,000. G&S Capital LLC purchased a new position in shares of iShares iBoxx $ Investment Grade Corporate Bond ETF in the fourth quarter valued at $114,000. Finally, We Are One Seven LLC purchased a new position in shares of iShares iBoxx $ Investment Grade Corporate Bond ETF in the fourth quarter valued at $126,000.

Get iShares iBoxx $ Investment Grade Corporate Bond ETF alerts:

Shares of NYSEARCA LQD opened at $116.41 on Monday. iShares iBoxx $ Investment Grade Corporate Bond ETF has a fifty-two week low of $111.25 and a fifty-two week high of $117.47.

The business also recently declared a monthly dividend, which was paid on Thursday, March 7th. Stockholders of record on Monday, March 4th were given a $0.3584 dividend. The ex-dividend date was Friday, March 1st. This is a boost from iShares iBoxx $ Investment Grade Corporate Bond ETF’s previous monthly dividend of $0.35. This represents a $4.30 annualized dividend and a dividend yield of 3.69%.

COPYRIGHT VIOLATION WARNING: This report was first reported by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/4213641/nelson-van-denburg-campbell-wealth-management-group-llc-raises-holdings-in-ishares-iboxx-investment-grade-corporate-bond-etf-lqd.html.

iShares iBoxx $ Investment Grade Corporate Bond ETF Profile

iShares iBoxx $ Investment Grade Corporate Bond ETF (the Fund), formerly iShares iBoxx $ Investment Grade Corporate Bond Fund, is an exchange-traded fund (ETF). The Fund seeks to track the investment results of the Markit iBoxx USD Liquid Investment Grade Index (the Index), which is a rules-based index consisting of liquid, the United States dollar-denominated, investment-grade corporate bonds for sale in the United States.

See Also: Insider Trading

Want to see what other hedge funds are holding LQD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares iBoxx $ Investment Grade Corporate Bond ETF (NYSEARCA:LQD).

Gray TV Beats Netflix

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-1045286234&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1045286234/960x0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; .

Gray Television, Inc. is beating Netflix big time on Wall Street, over the last twelve months.

Since last March, Gray TV&a;rsquo;s shares have gained 61.49%, while Netflix&a;rsquo;s shares have gained 8.86% (see chart).

That&a;rsquo;s a big change from previous years, when Netflix&a;rsquo;s stock beat Gray TV&a;rsquo;s by a big margin. In fact, Netflix&a;rsquo;s stock had been among the top winners in Wall Street over several years.

&l;img class=&q;size-large wp-image-19634&q; src=&q;http://blogs-images.forbes.com/panosmourdoukoutas/files/2019/03/koyfin_20190310_081528473-1200x600.jpg?width=960&q; alt=&q;&q; data-height=&q;600&q; data-width=&q;1200&q;&g; Gray TV vs Netflix Shares On Wall Street

Gray TV&a;rsquo;s lead over Netflix may come as a surprise to the momentum crowd on Wall Street. It is a traditional television and broadcasting company that Netflix seeks to replace with streaming services.

What could explain the change in fortunes between the two companies?

Multi-localization. Gray TV has been busy acquiring local TV stations around the US&l;span&g;. As &a;nbsp;of February, 2017, it owned and operated television stations in 57 markets, covering 10.4% of US households, according to its 2017 Annual Report.&l;/span&g;

&l;span&g;The company has been growing by &a;ldquo;leveraging its diverse national footprint broadcasting over 200 separate programming streams,&a;rdquo; according to the report. Like 100 affiliates of the &a;ldquo;Big Four&a;rdquo; networks, CBS Network, the NBC Network, the ABC Network, and the FOX Network. This diversification has allowed Gray TV to achieve leadership positions in local markets.&l;/span&g;

&l;span&g;&a;ldquo;We believe there are significant advantages in operating the #1 or #2 television broadcasting stations in a local market,&a;rdquo; says the company&a;rsquo;s 2017 report. &a;ldquo;Strong audience and market share allows us to enhance our advertising revenue through price discipline and leadership. We believe a top-rated news platform is critical to capturing incremental sponsorship and political advertising revenue.&a;rdquo;&l;/span&g;

&l;span&g;Meanwhile, Gray TV has been expanding the scale and scope of its operations by acquiring local TV stations. For the period 2013-17, for instance, the company made 23 acquisitions, adding a net total of 51 television stations -- in 31 markets -- to its operations, including 26 new television markets.&l;/span&g;

&l;span&g;That&a;rsquo;s a radically different strategy from Netflix&a;rsquo;s strategy, which relies on globalization rather than localization; and on subscription revenues rather than advertising monetization model. As of Q4 2018, Netflix had over 148 million subscribers worldwide, according to Statista.&l;/span&g;

&l;span&g;As it turns out, Gray TV&a;rsquo;s business model is more profitable than Netflix&a;rsquo;s, as reflected in the operating margins of the two companies. Gray TV&a;rsquo;s Gross Margins are 45% compared to 36.9% of Netflix&a;rsquo;s (see chart).&l;/span&g;

&l;img class=&q;size-large wp-image-19635&q; src=&q;http://blogs-images.forbes.com/panosmourdoukoutas/files/2019/03/koyfin_20190310_083131486-1200x600.jpg?width=960&q; alt=&q;&q; data-height=&q;600&q; data-width=&q;1200&q;&g; Gray TV and Netflix Gross Margins

&l;span&g;Meanwhile, Gray TV&a;rsquo;s low valuation (see chart) make it a better buy than Netflix for conservative investors.&l;/span&g;

&l;img class=&q;size-large wp-image-19637&q; src=&q;http://blogs-images.forbes.com/panosmourdoukoutas/files/2019/03/koyfin_20190310_083331215-1200x600.jpg?width=960&q; alt=&q;&q; data-height=&q;600&q; data-width=&q;1200&q;&g; Gray TV and Netflix Valuation

&l;span&g;&a;nbsp;&l;/span&g;

&l;/p&g;

Why Sierra Wireless Stock Dropped 18.9% in February

What happened

Shares of Sierra Wireless (NASDAQ:SWIR) fell 18.9% in February, according to data from S&P Global Market Intelligence, after the Internet of Things company announced underwhelming fourth-quarter 2018 results and disappointing forward guidance.

To be sure, Sierra Wireless stock plummeted as much as 25% on Feb. 14, 2019, alone -- the first trading day after its report hit the wires -- before recouping a small fraction of those losses over the remainder of the month.

IMAGE SOURCE: GETTY IMAGES.

So what

That's not to say Sierra Wireless' quarter looked terrible at first glance. Revenue climbed 9.7% year over year to $201.4 million, translating to adjusted net income of $9 million, or $0.25 per share, down from $0.28 per share in the same year-ago period. However, both figures were near the low ends of Sierra Wireless' own financial guidance, which called for revenue of $200 million to $208 million, and adjusted earnings per share of $0.22 to $0.30.

Now what

Arguably more concerning for investors, however, was Sierra Wireless CEO Kent Thexton's warning that the company is enduring a difficult macroeconomic environment and "some weakness... in the automotive, enterprise networking and mobile computing markets." 

As such, Sierra Wireless told investors to expect revenue in the first quarter of 2019 to be in the range of $170 million to $174 million, down from $186.9 million a year earlier, with adjusted earnings per share of $0.02 to $0.06. Both ranges fell well short of analysts' consensus estimates for first-quarter earnings of $0.21 per share on revenue of $198.2 million.

Also of note, Sierra Wireless is undertaking a new cost-reduction program over the next 18 to 24 months -- a move that should maximize its profits and resources to continue developing innovative IoT solutions even as top-line growth languishes.

Nonetheless, it's hard to blame the market for reacting negatively to the news last month. 

Why Intuit Stock Rose 14.5% in February

What happened

Shares of Intuit (NASDAQ:INTU) popped nearly 15% last month, according to data provided by S&P Global Market Intelligence, as investors cheered the tax, accounting, and personal finance software company's solid second-quarter results.

So what

Intuit's fiscal second-quarter revenue rose 12% to $1.5 billion. That was slightly above Wall Street's expectations of $1.48 billion. Adjusted earnings per share, meanwhile, jumped 19% to $1.00. That too exceeded analysts' projections, which had called for adjusted EPS of $0.86.

Intuit is enjoying broad-based growth. Revenue in its small-business and self-employed group -- which includes Intuit's popular QuickBooks accounting software -- leapt 17% to $833 million. And revenue in its consumer group -- which includes TurboTax, the leading do-it-yourself tax preparation software -- grew by 11%, to $461 million.

Notably, the number of QuickBooks Online subscribers climbed 38% to nearly 3.9 million subscribers. This rapidly growing area of Intuit's business is expected to be the company's most important growth driver in the coming years. "We believe the best measure of the health and success of our strategy going forward is online ecosystem revenue growth, which we continue to expect to grow better than 30%," CFO Michelle Clatterbuck said during Intuit's second-quarter conference call. 

Intuit's online services revenue is expanding at an impressive rate. Image source: Getty Images.

Now what

Intuit's stock price is now up nearly 25% so far in 2019 -- and that's on top of a 25% increase last year. The gains appear to be warranted, judging by Intuit's solid operating performance. But with shares now trading for about 33 times forward earnings, investors may want to wait for a pullback before initiating -- or adding to -- their positions.

Top 10 Value Stocks To Watch For 2019

tags:SYX,TSN,WIT,ADUS,AQXP,EXPD,CIM,BPT,UBNK,KEY, An early cheerleader for bitcoin has announced it's pulling the plug on the digital currency.

Leading online payments company Stripe said it will stop processing bitcoin transactions in April.

Stripe, which works with more than 100,000 businesses around the world, said it made the decision because huge volatility in bitcoin's price has made it pretty impractical for making and receiving payments.

"Bitcoin has evolved to become better-suited to being an asset than being a means of exchange," Stripe executive Tom Karlo wrote in a company blog post Tuesday.

Stripe's withdrawal of support comes on the back of bitcoin's wild ride over the last year or so.

Over the course of 2017, its price surged from under $1,000 to more than $19,000 at one point. It's plunged back to around $10,000 during tumultuous trading this month.

Experts say that the violent swings make bitcoin less useful as a currency and more of a vehicle for speculators to bet on its future value.

Top 10 Value Stocks To Watch For 2019: Systemax Inc.(SYX)

Advisors' Opinion:

• [By Joseph Griffin]

  Systematic Financial Management LP lowered its position in shares of Systemax Inc. (NYSE:SYX) by 4.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 44,315 shares of the company’s stock after selling 2,150 shares during the quarter. Systematic Financial Management LP owned 0.12% of Systemax worth $1,265,000 as of its most recent SEC filing.

• [By Lisa Levin] Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares rose 35.8 percent to $4.55. EVINE Live Inc. (NASDAQ: EVLV) gained 28.8 percent to $1.04. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet. Sanmina Corp (NASDAQ: SANM) shares surged 19.1 percent to $33.00 as the company reported stronger-than-expected earnings for its second quarter on Monday. Heidrick & Struggles International, Inc. (NASDAQ: HSII) gained 14.9 percent to $37.22 as the company posted upbeat results for its first quarter. Santander Consumer USA Holdings Inc. (NYSE: SC) shares climbed 14 percent to $17.90 following upbeat quarterly earnings. Helix Energy Solutions Group, Inc. (NYSE: HLX) climbed 14 percent to $7.12 following strong quarterly results. Check-Cap Ltd. (NASDAQ: CHEK) gained 13.6 percent to $8.25. Atossa Genetics Inc. (NASDAQ: ATOS) rose 11.8 percent to $3.34. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men. Cadence Design Systems, Inc. (NASDAQ: CDNS) gained 11.6 percent to $40.99 after the company posted upbeat Q1 results and issued a strong Q2 forecast. Genprex, Inc. (NASDAQ: GNPX) climbed 11.2 percent to $4.9363. Mitel Networks Corporation (NASDAQ: MITL) rose 10.5 percent to $11.23 after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion. Systemax Inc. (NYSE: SYX) rose 10.2 percent to $30.86. Sidoti & Co. upgraded Systemax from Neutral to Buy. Orchids Paper Products Company (NYSE: TIS) surged 9.2 percent to $7.13. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018. New Oriental Education & Technology Group Inc. (NYSE: EDU) rose
• [By Joseph Griffin]

  Systemax (NYSE:SYX) was upgraded by stock analysts at Sidoti from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The firm currently has a $45.00 price target on the stock. Sidoti’s price target indicates a potential upside of 19.78% from the company’s current price. The analysts noted that the move was a valuation call.

Top 10 Value Stocks To Watch For 2019: Tyson Foods Inc.(TSN)

Advisors' Opinion:

• [By ]

  Pilgrim's Pride (PPC) : "There are so many things wrong with this one. I'd go with Tyson Foods (TSN) ."

  JB Hunt Transport Services (JBHT) : "I'm sticking with it."

• [By Stephan Byrd]

  Systematic Financial Management LP boosted its position in Tyson Foods, Inc. (NYSE:TSN) by 16.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 115,734 shares of the company’s stock after acquiring an additional 16,022 shares during the quarter. Systematic Financial Management LP’s holdings in Tyson Foods were worth $8,471,000 at the end of the most recent reporting period.

• [By Logan Wallace]

  Franklin Resources Inc. cut its holdings in shares of Tyson Foods, Inc. (NYSE:TSN) by 88.7% during the first quarter, HoldingsChannel.com reports. The firm owned 58,511 shares of the company’s stock after selling 460,578 shares during the quarter. Franklin Resources Inc.’s holdings in Tyson Foods were worth $4,283,000 at the end of the most recent quarter.

Top 10 Value Stocks To Watch For 2019: Wipro Limited(WIT)

Advisors' Opinion:

• [By Ethan Ryder]

  Wipro (NYSE:WIT) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “WIPRO LTD-ADR provides comprehensive IT solutions and services, including systems integration, Information Systems outsourcing, package implementation, software application development and maintenance, and research and development services to corporations globally. Wipro Limited is the first PCMM Level 5 and SEI CMM Level certified IT Services Company globally. “

• [By Lisa Levin] Companies Reporting Before The Bell Thermo Fisher Scientific Inc. (NYSE: TMO) is projected to report quarterly earnings at $2.4 per share on revenue of $5.63 billion. Ford Motor Company (NYSE: F) is expected to report quarterly earnings at $0.41 per share on revenue of $37.16 billion. Twitter, Inc. (NYSE: TWTR) is projected to report quarterly earnings at $0.11 per share on revenue of $605.26 million. Comcast Corporation (NASDAQ: CMCSA) is expected to report quarterly earnings at $0.59 per share on revenue of $22.75 billion. General Dynamics Corporation (NYSE: GD) is estimated to report quarterly earnings at $2.52 per share on revenue of $7.6 billion. The Boeing Company (NYSE: BA) is expected to report quarterly earnings at $2.58 per share on revenue of $22.24 billion. Anthem, Inc. (NYSE: ANTM) is estimated to report quarterly earnings at $4.91 per share on revenue of $22.52 billion. Viacom, Inc. (NASDAQ: VIAB) is projected to report quarterly earnings at $0.79 per share on revenue of $3.04 billion. Northrop Grumman Corporation (NYSE: NOC) is estimated to report quarterly earnings at $3.61 per share on revenue of $6.61 billion. Rockwell Automation Inc. (NYSE: ROK) is expected to report quarterly earnings at $1.81 per share on revenue of $1.66 billion. Wipro Limited (NYSE: WIT) is projected to report quarterly earnings at $0.07 per share on revenue of $2.15 billion. The Goodyear Tire & Rubber Company (NASDAQ: GT) is expected to report quarterly earnings at $0.46 per share on revenue of $3.82 billion. Owens Corning (NYSE: OC) is projected to report quarterly earnings at $0.97 per share on revenue of $1.62 billion. T. Rowe Price Group, Inc. (NASDAQ: TROW) is estimated to report quarterly earnings at $1.71 per share on revenue of $1.29 billion. Dr Pepper Snapple Group, Inc. (NYSE: DPS) is expected to report quarterly earnings at $1.04 per share on revenue of $1.57 billion. Sirius XM Holdings Inc. (NASDAQ: SI
• [By Shane Hupp]

  Wipro Limited (NYSE:WIT) has been given an average rating of “Hold” by the eleven brokerages that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating on the company.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Wipro (WIT)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Joseph Griffin]

  Wipro Limited (NYSE:WIT) – Equities research analysts at Jefferies Financial Group issued their FY2019 earnings per share estimates for Wipro in a research report issued to clients and investors on Tuesday, June 19th. Jefferies Financial Group analyst A. Sen expects that the information technology services provider will post earnings of $0.29 per share for the year. Jefferies Financial Group currently has a “Underperform” rating on the stock. Jefferies Financial Group also issued estimates for Wipro’s FY2020 earnings at $0.30 EPS.

• [By Lisa Levin] Companies Reporting Before The Bell United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion. The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion. Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion. Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion. Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion. The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion. Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion. 3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion. JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion. Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion. Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion. Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion. Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion. The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion. Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion. PACCAR Inc (NASDAQ: PCAR) is projected to

Top 10 Value Stocks To Watch For 2019: Addus HomeCare Corporation(ADUS)

Advisors' Opinion:

• [By Ethan Ryder]

  BidaskClub upgraded shares of Addus Homecare (NASDAQ:ADUS) from a buy rating to a strong-buy rating in a report published on Saturday.

  Several other equities analysts have also recently weighed in on the stock. Stephens set a $56.00 price target on shares of Addus Homecare and gave the company a buy rating in a research report on Monday, April 2nd. Robert W. Baird set a $43.00 price target on shares of Addus Homecare and gave the company a hold rating in a research report on Wednesday, March 14th. ValuEngine raised shares of Addus Homecare from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research cut shares of Addus Homecare from a buy rating to a strong sell rating in a research report on Monday, June 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $51.00.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Addus Homecare (ADUS)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Motley Fool Transcribers]

  Addus HomeCare Corp  (NASDAQ:ADUS)Q4 2018 Earnings Conference CallMarch 05, 2019, 9:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Max Byerly]

  Addus Homecare Co. (NASDAQ:ADUS) CFO Brian Poff sold 2,098 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $65.41, for a total transaction of $137,230.18. Following the sale, the chief financial officer now directly owns 19,457 shares of the company’s stock, valued at approximately $1,272,682.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

• [By Joseph Griffin]

  Addus HomeCare (NASDAQ:ADUS) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a report issued on Saturday.

Top 10 Value Stocks To Watch For 2019: Aquinox Pharmaceuticals, Inc.(AQXP)

Advisors' Opinion:

• [By Stephan Byrd]

  These are some of the news headlines that may have effected Accern’s scoring:

  Get Aquinox Pharmaceuticals alerts: Analysts Offer Insights on Healthcare Companies: Portola Pharma (NASDAQ: PTLA), Rhythm Pharmaceuticals Inc … (analystratings.com) Aquinox Pharmaceuticals, Inc. (AQXP) -Importance of Lower Price to Sales Ratio (P/S) (topdesertsafari.com) Aquinox Pharmaceuticals (AQXP) Issues Quarterly Earnings Results (americanbankingnews.com) Aquinox Pharmaceuticals Announces Second Quarter 2018 Financial Results (finance.yahoo.com) Aquinox: 2Q Earnings Snapshot (finance.yahoo.com)

  A number of equities research analysts have recently issued reports on AQXP shares. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a research note on Tuesday, May 8th. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 15th. ValuEngine upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Aquinox Pharmaceuticals in a research note on Wednesday, June 27th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $20.80.

• [By Steve Symington]

  Still, some individual companies fared worse than most. Read on to learn why Sonic Corporation (NASDAQ:SONC), National Beverage (NASDAQ:FIZZ), and Aquinox Pharmaceuticals (NASDAQ:AQXP) plunged today.

• [By Max Byerly]

  Shares of Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) have received an average recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $25.25.

• [By Logan Wallace]

  Aquinox Pharmaceuticals (NASDAQ:AQXP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Monday.

• [By Ethan Ryder]

  Cantor Fitzgerald reiterated their neutral rating on shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) in a research report report published on Wednesday, MarketBeat.com reports.

• [By Chris Lange]

  Aquinox Pharmaceuticals Inc. (NASDAQ: AQXP) saw its shares crash on Wednesday after the firm gave a disappointing update for a late-stage trial. Unfortunately, the firm's Phase 3 LEADERSHIP 301 clinical trial evaluating rosiptor (AQX-1125) for the treatment of interstitial cystitis/bladder pain syndrome failed to meet its primary endpoint.

Top 10 Value Stocks To Watch For 2019: Expeditors International of Washington, Inc.(EXPD)

Advisors' Opinion:

• [By Stephan Byrd]

  Pensionfund DSM Netherlands cut its holdings in shares of Expeditors International of Washington (NASDAQ:EXPD) by 31.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,400 shares of the transportation company’s stock after selling 14,600 shares during the quarter. Pensionfund DSM Netherlands’ holdings in Expeditors International of Washington were worth $2,309,000 as of its most recent filing with the Securities & Exchange Commission.

• [By Max Byerly]

  Pensionfund Sabic reduced its stake in shares of Expeditors International of Washington (NASDAQ:EXPD) by 30.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,800 shares of the transportation company’s stock after selling 10,000 shares during the quarter. Pensionfund Sabic’s holdings in Expeditors International of Washington were worth $1,676,000 as of its most recent SEC filing.

• [By Max Byerly]

  The Manufacturers Life Insurance Company boosted its stake in shares of Expeditors International of Washington (NASDAQ:EXPD) by 22.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 240,918 shares of the transportation company’s stock after purchasing an additional 44,645 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.14% of Expeditors International of Washington worth $15,249,000 at the end of the most recent reporting period.

• [By Ethan Ryder]

  COPYRIGHT VIOLATION NOTICE: “Expeditors International of Washington (EXPD) Shares Sold by SG Americas Securities LLC” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/4141348/expeditors-international-of-washington-expd-shares-sold-by-sg-americas-securities-llc.html.

• [By Joseph Griffin]

  Get a free copy of the Zacks research report on Expeditors International of Washington (EXPD)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Value Stocks To Watch For 2019: Chimera Investment Corporation(CIM)

Advisors' Opinion:

• [By Motley Fool Transcribers]

  Chimera Investment Corp  (NYSE:CIM)Q4 2018 Earnings Conference CallFeb. 13, 2019, 9:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Shane Hupp]

  Public Employees Retirement Association of Colorado trimmed its position in shares of Chimera Investment Co. (NYSE:CIM) by 18.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 51,307 shares of the real estate investment trust’s stock after selling 11,267 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Chimera Investment were worth $893,000 at the end of the most recent reporting period.

• [By Jon C. Ogg]

  Chimera Investment Corp. (NYSE: CIM) was downgraded to Hold from Buy at Deutsche Bank.

  Comerica Inc. (NYSE: CMA) was downgraded to Market Perform from Outperform with an $83 price target (versus an $84.47 close) at BMO Capital Markets.

Top 10 Value Stocks To Watch For 2019: BP Prudhoe Bay Royalty Trust(BPT)

Advisors' Opinion:

• [By Dan Caplinger]

  Sometimes, though, you can have too much of a good thing. Dividend stocks with top dividend yields come with special risks, and although that doesn't guarantee that you'll get burned, the chances of a setback are greater. Below, I'll look at BP Prudhoe Bay Royalty Trust (NYSE:BPT), CenturyLink (NYSE:CTL), and Annaly Capital Management (NYSE:NLY) to explain why their yields are so high and what dangers could lurk beneath the surface.

• [By Joseph Griffin]

  News headlines about BP Prudhoe Bay Royalty Trust (NYSE:BPT) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BP Prudhoe Bay Royalty Trust earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the oil and gas company an impact score of 46.2072909143413 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

• [By Dan Caplinger]

  The stock market had a tumultuous session on Wednesday, as major benchmarks started the day weak but bounced back in the afternoon. Investors weren't happy with the current state of geopolitical uncertainty, with trade disputes threatening to become larger problems than ever. But the release of the minutes of the latest meeting of the Federal Reserve's monetary policy committee convinced many that the central bank will be slow to do lasting damage to the economic expansion, remaining measured in the pace of its interest rate increases. Moreover, some companies had good news that sent their shares higher. Tiffany (NYSE:TIF), BP Prudhoe Bay Royalty Trust (NYSE:BPT), and Ralph Lauren (NYSE:RL) were among the best performers on the day. Here's why they did so well.

Top 10 Value Stocks To Watch For 2019: United Financial Bancorp Inc.(UBNK)

Advisors' Opinion:

• [By Motley Fool Staff]

  United Financial Bancorp (NASDAQ:UBNK) Q2 2018 Earnings Conference CallJul. 18, 2018 10:00 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Max Byerly]

  United Financial Bancorp (NASDAQ:UBNK) will post its quarterly earnings results before the market opens on Tuesday, October 16th. Analysts expect United Financial Bancorp to post earnings of $0.30 per share for the quarter.

• [By Ethan Ryder]

  United Financial Bancorp (NASDAQ:UBNK) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “United Financial Bancorp, Inc. is the holding company for United Bank, a full service financial services firm offering a complete line of commercial, business, and consumer banking products and services. The Company is primarily engaged in the business of directing, planning, and coordinating the business activities of the Bank. United Financial Bancorp, Inc. is based in Connecticut. “

• [By Max Byerly]

  Hennessy Advisors Inc. cut its holdings in United Financial Bancorp Inc (NASDAQ:UBNK) by 4.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 235,000 shares of the bank’s stock after selling 10,000 shares during the quarter. Hennessy Advisors Inc.’s holdings in United Financial Bancorp were worth $3,955,000 as of its most recent SEC filing.

Top 10 Value Stocks To Watch For 2019: KeyCorp(KEY)

Advisors' Opinion:

• [By Max Byerly]

  BOK Financial (NASDAQ:BOKF) and KeyCorp (NYSE:KEY) are both finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

• [By Stephan Byrd]

  Gifford Fong Associates acquired a new stake in shares of KeyCorp (NYSE:KEY) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 30,000 shares of the financial services provider’s stock, valued at approximately $587,000.

• [By Max Byerly]

  Get a free copy of the Zacks research report on KeyCorp (KEY)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Why Ambarella Stock Popped Today

What happened

Shares of Ambarella (NASDAQ:AMBA) climbed as much as 11% early Wednesday, then settled to trade up 8.1% as of 2:45 p.m. EST after the video-processing chip specialist announced strong fiscal fourth-quarter 2019 earnings.

That's not to say Ambarella's quarter was perfect. On one hand, revenue declined 28% year over year to $51.1 million, just missing Wall Street's consensus estimates for sales closer to $52 million. But on the other hand, Ambarella's adjusted (non-GAAP) earnings fell to $4.5 million, or $0.14 per share, down from $0.47 per share in the same year-ago period but well above the $0.04 per share most analysts were modeling.

IMAGE SOURCE: AMBARELLA.

So what

During the subsequent conference call, management noted that revenue from the security camera market actually increased around 10% year over year. But the consumer electronics industry fell faster than expected throughout the year, representing virtually all the company's year-over-year declines. Still, during the annual Consumer Electronics Show in January, Ambarella took the opportunity to demonstrate its latest computer-vision chip solutions with a particular focus on penetrating the automotive industry.

"Strategically, fiscal 2019 was one of the most important years in Ambarella's 15 year history as the company continued to execute on its transformation from a pure video processing company to a computer vision company," stated Ambarella CEO Fermi Wang. "We taped-out and sampled three 10nm computer vision system-on-a-chip devices and commenced mass production of one of the devices, all in the fiscal year."

Now what

For the first quarter of the new fiscal year 2020 -- and noting the company is still battling a decline in consumer electronics revenue as well as macroeconomic headwinds -- Ambarella expects revenue to be roughly $47 million, plus or minus 3%, down from roughly $57 million in the same year-ago period.

Even so, given Ambarella's progress in the computer vision markets, its bottom-line outperformance in the fourth quarter, and with shares down more than 20% over the past year leading up to this report, it's no surprise to see investors bidding up Ambarella stock today.

The 3 Oldest Members of Biotech's Billion-Burned Club

Believe it or not, most professionals in the weird world of drug development would rather be lucky than smart. That's because 99.99% of potential new drugs that look great in a petri dish eventually lose their luster before earning a nickel.  

Every time an attempt to develop a new revenue source fails, it costs something. The biotech industry is especially cruel, because each step toward success is exponentially more expensive than the one before it. 

These three start-ups have gotten close more than once, but they still don't have any products to sell. What they have created, though, is a trail of disappointed investors who have watched at least $1 billion go up in flames.

Company (Symbol) Market Capitalization Year of Incorporation Accumulated Deficit, Sept. 30, 2018 Focus

Novavax (NASDAQ:NVAX)	$269 million	1987	$1.25 billion	Vaccines
Geron (NASDAQ:GERN)	$285 million	1990	$1.00 billion	Oncology
Agenus (NASDAQ:AGEN)	$405 million	1994	$1.13 billion	Vaccines/oncology

Data source: company SEC filings.

There are biopharma companies that have been around longer and burned through more of their investors' cash, but those stocks have been beaten into the dirt in less time. Here's what you need to know about three struggling biotechs that still have a long way to fall.

Novavax: Vaccine math is hard

Proving that a new experimental vaccine will provide a meaningful benefit in the real world isn't easy. Respiratory syncytial virus (RSV) is a relatively common infection, but it only sends around 2% of infants, and their distraught parents, to seek treatment for severe pneumonia.

To convince regulators that an RSV vaccine provides a meaningful level of protection for a slim number of potentially susceptible patients requires one of two things to happen. Your vaccine needs to protect nearly everyone from infection, or else you need to test enough patients to fill a football stadium. 

While there are signs that ResVax prevents severe RSV infections, the company will almost certainly have to run a much larger study to persuade the FDA to consider approval. After burning through $1 billion with hardly a thing to show for it, Novavax could have a hard time persuading investors to back another attempt.

Image source: Getty Images.

Geron: What good's a clock without a calendar?

Telomerases that connect chromosomes are supposed to get shorter each time a cell divides, but malignant cells usually find a way to extend theirs. Geron's been trying to prove that it can control these molecular clocks, which would also make it tough for cancer to progress.

While Geron's been trying to control tiny molecular clocks, it hasn't been keeping an eye on the calendar. The company switched gears to intravenously administered imetelstat after an autologous cellular vaccine candidate fizzled out more than a decade ago. Over the years, Geron's tried imetelstat as a treatment for lung cancer, brain cancer, breast cancer, and a handful of blood cancers without much luck.

Imetelstat's most recent flop was with myelofibrosis patients who relapse after standard care. This group needs a new treatment option, but it doesn't look as if Geron's going to provide it. in September, Johnson & Johnson (NYSE:JNJ) walked away from an important imetelstat licensing deal after just 10% of patients receiving the high dosage during a mid-stage study achieved the trial's main goal -- a 35% smaller spleen.

Geron's going to keep swinging with imetelstat. After J&J walked away, the company decided to begin the phase 3 portion of an ongoing phase 2 study for low to intermediate risk patients with myelodysplastic syndromes (MDS) or failing bone marrow. MDS patients rely on red blood cell transfusions that are expensive and painful, plus one in three develop an aggressive form of leukemia.

An impressive 26% of patients treated with imetelstat were able to go at least 24 weeks without a transfusion, and 71% became measurably less dependent. The phase 3 portion will finally include a placebo group for comparison, and a significant improvement could bring a potential partner back to the table. After a couple of decades without a win, though, it probably isn't worth the risk.

Image source: Getty Images.

Agenus: Shotgun approach

In stark contrast to Geron, Agenus is guilty of running more programs than it can afford. The company's vaccine booster is a component of GlaxoSmithKline's (NYSE:GSK) new shingles vaccine, Shingrix. Agenus was entitled to a single-digit percentage of blockbuster Shingrix sales, but it sold all rights to those royalties last year in return for $190 million up front. 

The company's lead candidate is a PD-1 checkpoint inhibitor that already has plenty of well-established competitors that work the same way. That means clinical trial results that are anything less than spectacular will end any chance of significant sales. Agenus recently launched a blockchain-based "coin" that entitles investors to a portion of U.S. net sales, if there are any. Those intrigued by this interesting concept should probably wait until it's applied to a potential new drug that isn't trying to become the 19th member of its class to reach a limited market.

In December, Agenus received $150 million from Gilead Sciences (NASDAQ:GILD) in return for exclusive rights to an oncology candidate that hadn't even entered clinical trials, plus an option to license two more pre-clinical stage candidates. The cash injection came at a good time. The company finished September with just $46 million in cash after burning through $112 million during the first nine months of 2018.

Image source: Getty Images.

Equity is more expensive than it seems

Some biopharmaceutical companies can marinate for two decades before they start to sizzle, but raising equity by offering shares can make it impossible for long-term investors to realize a satisfactory return on their investment.

In the past decade alone, Geron shareholders have seen their share of any future profits cut in half, which isn't nearly as bad as Agenus and Novavax. Secondary offerings have boosted Novavax's share count 456% over the same time frame, and Agenus' has risen tenfold.

While there's always a slim chance of success with these aging start-ups, it isn't hard to find better options.

4 Simple Tricks For Saving More Money

Saving money cam be challenging no matter how much you earn. After all, you probably have a lot of immediate expenses, and can think of many more fun things to do with your dollars than stick them into a savings account. 

But overcoming these challenges is important. In fact, saving money is essential to accomplish long-term goals, and even to make big purchases in the short-term. You should be saving money for lots of different things, from retirement to the purchase of your next car to your next big vacation -- and to save enough for all these goals, you've got to have a lot of money left over after paying the bills. 

The good news is that there are ample ways you can increase the amount you save, often without making major changes to your lifestyle. Here are four suggestions that can help.

Image source: Getty Images.

1. Take full advantage of coupons and deals

There are endless bargains to be had if you only know where to look.

You can save on the costs of everyday items, including food, toiletries, and personal items, by using coupons from the Sunday paper. And you don't have to buy a paper and spend all day clipping coupons to get these savings either -- you can take advantage of websites such as The Coupon Clippers or Klip2save that allow you to pay a small cost to have coupons mailed to you. By using these sites, you save time, and can choose to get coupons only for products you'd purchase anyway so you aren't buying a bunch of junk just because you might save a few cents on it.  

Before shopping online or in any retail store, it's also a good idea to do a quick search for a printable coupon or coupon code. It takes a few seconds to do a search, and you can often find coupons for a percentage off your purchase or for free shipping. Apps such as Honey also do this automatically, finding coupons, special deals, and promo codes on items you're shopping for so you don't even have to turn to a search engine. 

If you're able to save money on everyday purchases, you'll have more left in your bank account that you can use to save for big goals.  

2. Buy used or borrow instead of buying

Have you ever bought something, such as a tool or a cleaning product, only to use it just once or twice a year? We have -- our garage is full of a things like power washers and chain saws and rug cleaners that we rarely touch. Instead of buying all of these items yourself, see if a family member or friend will let you borrow. Or arrange with a few neighbors to buy one item you all take turns using. You'll save a lot of space storing items you don't use often, and will save a lot of money too. 

When you do need to make a purchase, consider buying used instead of new. There are some things -- like mattresses and soft furniture in bedbug-prone areas -- that you don't want to buy used. And when safety is at stake, such as when you're looking for a children's car seat or high chair, you should buy new too.

But for many other items, purchasing brand new simply makes no sense. From sporting equipment to kids toys to dress-up attire, there are ample used options out there online and from local thrift or consignment stores that can save you a fortune. Once you learn where to shop and what days new items come in, you'll be able to get great bargains on items in perfect or near-perfect condition. Plus you get the thrill of the hunt, and the satisfaction of knowing you got things you needed at a great price. 

3. Be smarter about how you eat out

Giving up dining out could save you a lot of money, but it's a big lifestyle change. Fortunately, you don't have to swear off restaurants entirely to save more money. You just need to eat out in a smarter way.

First and foremost, skip the convenience meals that don't actually provide you with pleasure. If you make up a few extra servings of food each time you cook and freeze these meals, you can reach for them for lunches on workdays and quick dinners instead of stopping for take-out that you pay a premium for.  

And when you go out to meals you actually enjoy, you can cut costs on those as well. Consider a late lunch instead of dinner to get the same food at bargain prices. Skip the drinks, or have just a glass, to avoid the markup on alcohol. If you share a few appetizers and one entree, you'll keep your bill down and get to try more items on the menu. And when your favorite restaurants offer deals -- like bonus gift cards if you buy a gift card during the holidays -- take advantage of them. 

By being strategic with your dining-out dollars, your money will stretch further, and you can still enjoy a nice meal out on the town. 

4. Have dedicated savings accounts for each goal

Cutting spending is key to saving, and it's easier to do that if you're really motivated.

Being able to track your progress can help you stay inspired to hit your savings goals, so create separate accounts for each big thing you're saving for. That way, as you see your vacation fund, house fund, and retirement fund grow, you'll know that you're not just sacrificing for something abstract -- you're actually getting closer to affording important things. 

When you have dedicated savings accounts for specific goals, you're also much less likely to raid those accounts for other purposes than if you leave your savings in your checking account or have a general "savings account." And you can automate transfers of money to each account in accordance with how much you need to save to accomplish each specific goal on time.

By moving money automatically where it needs to go to save for different things, you can be sure you stay on track to hit your savings targets for each goal. 

You can save money easily with just a few simple changes

As you can see, saving money doesn't have to mean great sacrifice. By being smarter about how you buy things and transferring money to dedicated savings accounts, you can hopefully put aside more money each month and hit your savings goals faster than you imagined possible. 

Top 5 Casino Stocks To Invest In 2019

tags:NML,CUBA,NNC,RGLD,RUBI,

The owner of the Houston Rockets got into the blank-check game more than two years ago. He’s finally scored a deal.

A special purpose acquisition company run by Texas businessman Tilman Fertitta has agreed to buy food delivery startup Waitr Inc. for $300 million, according to a statement Wednesday.

Landcadia Holdings Inc. is paying Waitr’s backers at least $50 million in cash and the rest in stock in a deal that will bring the food-delivery company public.

Landcadia, which raised $300 million in its IPO in 2016, will change its name to Waitr Inc. and trade on the Nasdaq after the deal closes later this year. Waitr’s management will remain in place and Fertitta will join its board.

Fertitta is familiar with the restaurant and hospitality industries. He owns and runs casino operator Golden Nugget Inc. and steakhouse chain Landry’s Inc. The Houston native paid $2.2 billion last year for the Houston Rockets, the highest price ever paid for a National Basketball Association team.

Top 5 Casino Stocks To Invest In 2019: Neuberger Berman MLP Income Fund Inc.(NML)

Advisors' Opinion:

• [By Ethan Ryder]

  New Millennium Iron Corp (TSE:NML)’s share price reached a new 52-week low during trading on Monday . The stock traded as low as C$0.07 and last traded at C$0.07, with a volume of 21500 shares traded. The stock had previously closed at C$0.07.

• [By Logan Wallace]

  Neuberger Berman MLP Income Fund Inc (NYSEAMERICAN:NML) declared a monthly dividend on Monday, October 1st, Wall Street Journal reports. Investors of record on Monday, December 17th will be given a dividend of 0.055 per share by the investment management company on Monday, December 31st. This represents a $0.66 dividend on an annualized basis and a dividend yield of 7.42%. The ex-dividend date is Friday, December 14th.

Top 5 Casino Stocks To Invest In 2019: The Herzfeld Caribbean Basin Fund, Inc.(CUBA)

Advisors' Opinion:

• [By Stephan Byrd]

  Media headlines about Herzfeld Caribbean Basin Fund, Inc. common stock (NASDAQ:CUBA) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Herzfeld Caribbean Basin Fund, Inc. common stock earned a news sentiment score of 0.00 on Accern’s scale. Accern also gave news stories about the investment management company an impact score of 48.5554072096128 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Top 5 Casino Stocks To Invest In 2019: Nuveen North Carolina Premium Income Municipal Fund(NNC)

Advisors' Opinion:

• [By Ethan Ryder]

  Wells Fargo & Company MN increased its holdings in Nuveen North Carol Premium Incom Mun Fd (NYSE:NNC) by 29.8% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 289,655 shares of the financial services provider’s stock after purchasing an additional 66,507 shares during the quarter. Wells Fargo & Company MN’s holdings in Nuveen North Carol Premium Incom Mun Fd were worth $3,554,000 at the end of the most recent reporting period.

Top 5 Casino Stocks To Invest In 2019: Royal Gold Inc.(RGLD)

Advisors' Opinion:

• [By Joseph Griffin]

  Royal Gold (NASDAQ:RGLD) (TSE:RGL) – Equities research analysts at B. Riley increased their Q2 2019 earnings per share (EPS) estimates for Royal Gold in a research note issued on Tuesday, April 17th. B. Riley analyst L. Pipes now forecasts that the basic materials company will post earnings of $0.46 per share for the quarter, up from their previous estimate of $0.45. B. Riley also issued estimates for Royal Gold’s Q3 2019 earnings at $0.45 EPS, Q4 2019 earnings at $0.44 EPS and FY2020 earnings at $1.78 EPS.

• [By Max Byerly]

  Shares of Royal Gold, Inc (NASDAQ:RGLD) (TSE:RGL) have been assigned a consensus rating of “Buy” from the twelve ratings firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $94.39.

• [By Jon C. Ogg]

  Royal Gold Inc. (NASDAQ: RGLD) recently traded at $77.50, with a market cap of $5 billion. Its 52-week range is $76.02 to $98.53. The consensus target price of $96.42 may be $1.00 lower than a month earlier, but it’s actually right where the analyst community was 90 days ago. The analysts are still hoping for 24% upside here.

• [By Reuben Gregg Brewer, Travis Hoium, and Chuck Saletta]

  Penny stocks are exciting in a get-rich-quick kind of way. But the risks of something going wrong are huge. The penny stock space is replete with scam artists and small, financially weak companies. So we asked three Motley Fool investors to recommend stocks that are established, yet still quite exciting. If you're considering penny stocks, you might want to step back instead and take a look at Immersion Corporation (NASDAQ:IMMR), Melco Resorts & Entertainment Ltd. (NASDAQ:MLCO), and Royal Gold Inc. (NASDAQ:RGLD). Each of them opens up a huge opportunity, if you take the time to dig in just a little bit, without the risks that often show up with penny stocks. 

• [By Shane Hupp]

  Royal Gold, Inc (NASDAQ:RGLD) (TSE:RGL)’s share price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $71.91 and last traded at $72.84, with a volume of 11408 shares. The stock had previously closed at $72.94.

• [By Tyler Crowe, Matthew Frankel, CFP, and Neha Chamaria]

  So we asked three Motley Fool contributors to tell us about one of their favorite mid-cap stocks out there today. Here's why they picked real estate investment trust (REIT) Physicians Realty Trust (NYSE:DOC), precious metal streaming company Royal Gold (NASDAQ:RGLD), and solar power component supplier SolarEdge Technologies (NASDAQ:SEDG). 

Top 5 Casino Stocks To Invest In 2019: The Rubicon Project, Inc.(RUBI)

Advisors' Opinion:

• [By Motley Fool Transcription]

  The Rubicon Project, Inc. (NYSE:RUBI)Q4 2018 Earnings Conference CallFeb. 27, 2019, 4:30 p.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Ethan Ryder]

  Rubicon Project (NYSE: RUBI) is one of 44 publicly-traded companies in the “Computer programming, data processing, & other computer related” industry, but how does it weigh in compared to its competitors? We will compare Rubicon Project to related companies based on the strength of its analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk.

• [By Ethan Ryder]

  The Rubicon Project Inc (NYSE:RUBI) saw unusually-high trading volume on Wednesday . Approximately 1,541,600 shares traded hands during trading, an increase of 150% from the previous session’s volume of 615,518 shares.The stock last traded at $3.22 and had previously closed at $2.90.

• [By Max Byerly]

  Rubicon Project (NYSE:RUBI) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Wednesday.